BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cutaneous Sarcoidosis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Cutaneous Sarcoidosis
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06978725-1450@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Lisraya (brepocitinib): Phase 2/3 readout est. (NCT06978725)
DESCRIPTION:Lisraya (brepocitinib)\, phase 2/3\, Cutaneous Sarcoidosis.\nSt
 udy: A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis\nEstimat
 ed primary completion: 31 December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/brepocitinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06978725
URL:https://assetmemo.bio/drug/brepocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
